Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

BACKGROUND<br/> The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. <br/><br/>METHODS<br/> We performed...

ver descrição completa

Detalhes bibliográficos
Principais autores: Agnandji, S, Huttner, A, Zinser, M, Bejon, P
Formato: Journal article
Publicado em: Massachusetts Medical Society 2016